Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year? [Yahoo! Finance]
Context Therapeutics Inc. (CNTX)
Company Research
Source: Yahoo! Finance
Has Context Therapeutics Inc. (CNTX) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Context Therapeutics Inc. is a member of the Medical sector. This group includes 1019 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Context Therapeutics Inc. is currently sporting a Zacks Rank of #2 (Buy). Over the past three months, the Zacks Consensus Estimate for CNTX's full-year earnings has moved 15.3% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend. Our
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics Inc. (NASDAQ: CNTX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.MarketBeat
- Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 [Yahoo! Finance]Yahoo! Finance
- Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76GlobeNewswire
- Context Therapeutics names Andy Pasternak as chair [Seeking Alpha]Seeking Alpha
- Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of DirectorsGlobeNewswire
CNTX
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form 4
- CNTX's page on the SEC website